[Featured Stock] Curexo Rises on Expectations of Record-Breaking Medical Robot Sales
Curexo is showing strong performance. The stock price is rising as the securities industry forecasts that the company will break records in medical robot sales.
As of 10:17 AM on the 22nd, Curexo is trading at 13,010 KRW, up 8.75% from the previous day.
Curexo manufactures and sells self-developed medical robots such as knee joint replacement and spine surgery robots, as well as gait rehabilitation robots. In addition, the company also operates implant distribution business necessary for joint replacement surgery and a food raw material trading business.
Na Seungdoo, a researcher at SK Securities, stated, “Curexo started by selling 4 gait rehabilitation robots in 2019, and last year sold a total of 62 surgical and rehabilitation robots. The spread of the non-face-to-face trend due to the COVID-19 pandemic undoubtedly stimulated demand for medical robots. However, this year, the advantages and necessity of medical robots themselves have become more prominent, and the annual sales volume is expected to break records again.”
Hot Picks Today
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- Putin Arrives in Beijing, Begins Two-Day State Visit to China
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
He added, “This year, the medical robot sector will see growth led more by overseas markets than domestic ones, and surgical robots will drive growth more than rehabilitation robots. In particular, the knee joint surgery robot CUVIS-Joint has attracted global attention for adopting an open platform that is not limited to specific joint implants. Significant progress is expected in markets such as India and the United States.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.